This week's roundup of Houston innovators includes Sunny Zhang of TrueLeap, Jim Dillon of BiVACOR, and Livia Schiavinato Eberlin of Baylor College of Medicine. Photos courtesy

Editor's note: Each week, I'm introducing you to three Houston innovators to know — three individuals behind recent innovation and startup news stories in Houston as reported by InnovationMap. Learn more about them and their recent news below by clicking on each article.

Sunny Zhang, founder of TrueLeap

Sunny Zhang joins the Houston Innovators Podcast. Photo via LinkedIn

It's safe to say Sunny Zhang has a handle on the machine and cycle that innovation as a tenured business professor, startup founder, and venture capital investor. An academic at her core, she looks at innovation from the outside in — and inside out — in her various roles.

But there is a throughline for Zhang, and it's observing the innovation cycle. In her 20 years, she's worked closely with startups on the topic.

"My research has always focused on the innovation diffusion process — essentially the psychological and behavioral science of innovation diffusion when a product is introduced in a marketplace. How is that adoption going in a network as a result in many factors — internally and externally in a digital world and in the international and global market," Zhang says on the Houston Innovators Podcast.

"I've been seeing how innovation works, how products are getting adopted, and the behavioral process in it. We talk about 'go-to market,' but I want to promote 'come-from market.' Identify the problem itself," Zhang says, explaining that as both an academic and life-long learner, this is important to her.

Jim Dillon, CEO of BiVACOR

Jim Dillon has been named CEO of BiVACOR. Photo courtesy of BiVACOR

Houston-based medical device company BiVACOR has brought aboard a new CEO.

Jim Dillon, a longtime executive in the medical device sector, has been hired to lead BiVACOR and join its board of directors. Dillon succeeds former heart surgeon Dr. Thomas Vassiliades, whose appointment as CEO was announced in January 2022.

“Jim’s leadership style, combined with his experience in building high-performance teams as well as expertise in the heart failure field, makes him the ideal person to lead BiVACOR,” Raymond Cohen, chairman of BiVACOR, says in a news release. Continue reading.

Livia Schiavinato Eberlin, associate professor of surgery at Baylor College of Medicine

Livia Schiavinato Eberlin was named the 2024 recipient of the Norman Hackerman Award in Chemical Research. Photo via bcm.edu

An associate professor of surgery at Baylor College of Medicine has won a prestigious award for young chemical scientists in the state and secured $3 million in funding to further develop her technology.

Livia Schiavinato Eberlin was named the 2024 recipient of the Norman Hackerman Award in Chemical Research in December. The award was established by the Houston-based Welch Foundation and recognizes the accomplishments of chemical scientists in Texas who are early in their careers. Eberlin will be granted $100,000 for this honor.

Eberlin runs the Eberlin Lab for Medical Mass Spectrometry at BCM and is known for her groundbreaking work in the application of mass spectrometry technologies, which are changing how physicians treat cancer and analyze tissues.

In the same week, Baylor College of Medicine announced that the Eberlin Lab received $3 million in funding from The Marcus Foundation to further develop the MasSpec Pen technology in breast cancer surgeries. Eberlin developed the tool in 2016 while she was serving as an assistant professor at the University of Texas at Austin. The MasSpec Pen is a device for detecting cancer directly on tissues. Continue reading.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

MD Anderson makes AI partnership to advance precision oncology

AI Oncology

Few experts will disagree that data-driven medicine is one of the most certain ways forward for our health. However, actually adopting it comes at a steep curve. But what if using the technology were democratized?

This is the question that SOPHiA GENETICS has been seeking to answer since 2011 with its universal AI platform, SOPHiA DDM. The cloud-native system analyzes and interprets complex health care data across technologies and institutions, allowing hospitals and clinicians to gain clinically actionable insights faster and at scale.

The University of Texas MD Anderson Cancer Center has just announced its official collaboration with SOPHiA GENETICS to accelerate breakthroughs in precision oncology. Together, they are developing a novel sequencing oncology test, as well as creating several programs targeted at the research and development of additional technology.

That technology will allow the hospital to develop new ways to chart the growth and changes of tumors in real time, pick the best clinical trials and medications for patients and make genomic testing more reliable. Shashikant Kulkarni, deputy division head for Molecular Pathology, and Dr. J. Bryan, assistant professor, will lead the collaboration on MD Anderson’s end.

“Cancer research has evolved rapidly, and we have more health data available than ever before. Our collaboration with SOPHiA GENETICS reflects how our lab is evolving and integrating advanced analytics and AI to better interpret complex molecular information,” Dr. Donna Hansel, division head of Pathology and Laboratory Medicine at MD Anderson, said in a press release. “This collaboration will expand our ability to translate high-dimensional data into insights that can meaningfully advance research and precision oncology.”

SOPHiA GENETICS is based in Switzerland and France, and has its U.S. offices in Boston.

“This collaboration with MD Anderson amplifies our shared ambition to push the boundaries of what is possible in cancer research,” Dr. Philippe Menu, chief product officer and chief medical officer at SOPHiA GENETICS, added in the release. “With SOPHiA DDM as a unifying analytical layer, we are enabling new discoveries, accelerating breakthroughs in precision oncology and, most importantly, enabling patients around the globe to benefit from these innovations by bringing leading technologies to all geographies quickly and at scale.”

Houston company plans lunar mission to test clean energy resource

lunar power

Houston-based natural resource and lunar development company Black Moon Energy Corporation (BMEC) announced that it is planning a robotic mission to the surface of the moon within the next five years.

The company has engaged NASA’s Jet Propulsion Laboratory (JPL) and Caltech to carry out the mission’s robotic systems, scientific instrumentation, data acquisition and mission operations. Black Moon will lead mission management, resource-assessment strategy and large-scale operations planning.

The goal of the year-long expedition will be to gather data and perform operations to determine the feasibility of a lunar Helium-3 supply chain. Helium-3 is abundant on the surface of the moon, but extremely rare on Earth. BMEC believes it could be a solution to the world's accelerating energy challenges.

Helium-3 fusion releases 4 million times more energy than the combustion of fossil fuels and four times more energy than traditional nuclear fission in a “clean” manner with no primary radioactive products or environmental issues, according to BMEC. Additionally, the company estimates that there is enough lunar Helium-3 to power humanity for thousands of years.

"By combining Black Moon's expertise in resource development with JPL and Caltech's renowned scientific and engineering capabilities, we are building the knowledge base required to power a new era of clean, abundant, and affordable energy for the entire planet," David Warden, CEO of BMEC, said in a news release.

The company says that information gathered from the planned lunar mission will support potential applications in fusion power generation, national security systems, quantum computing, radiation detection, medical imaging and cryogenic technologies.

Black Moon Energy was founded in 2022 by David Warden, Leroy Chiao, Peter Jones and Dan Warden. Chiao served as a NASA astronaut for 15 years. The other founders have held positions at Rice University, Schlumberger, BP and other major energy space organizations.

Houston co. makes breakthrough in clean carbon fiber manufacturing

Future of Fiber

Houston-based Mars Materials has made a breakthrough in turning stored carbon dioxide into everyday products.

In partnership with the Textile Innovation Engine of North Carolina and North Carolina State University, Mars Materials turned its CO2-derived product into a high-quality raw material for producing carbon fiber, according to a news release. According to the company, the product works "exactly like" the traditional chemical used to create carbon fiber that is derived from oil and coal.

Testing showed the end product met the high standards required for high-performance carbon fiber. Carbon fiber finds its way into aircraft, missile components, drones, racecars, golf clubs, snowboards, bridges, X-ray equipment, prosthetics, wind turbine blades and more.

The successful test “keeps a promise we made to our investors and the industry,” Aaron Fitzgerald, co-founder and CEO of Mars Materials, said in the release. “We proved we can make carbon fiber from the air without losing any quality.”

“Just as we did with our water-soluble polymers, getting it right on the first try allows us to move faster,” Fitzgerald adds. “We can now focus on scaling up production to accelerate bringing manufacturing of this critical material back to the U.S.”

Mars Materials, founded in 2019, converts captured carbon into resources, such as carbon fiber and wastewater treatment chemicals. Investors include Untapped Capital, Prithvi Ventures, Climate Capital Collective, Overlap Holdings, BlackTech Capital, Jonathan Azoff, Nate Salpeter and Brian Andrés Helmick.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.